TACSTD2 and cervical cancer: Three primary cervical cancer cell lines (ie, CVX8 and ADX3, Trop-2 positive and ADX2, Trop-2 negative) (Supplementary Table 1) were used for in vitro viability assays in various concentrations of sacituzumab govitecan (hRS7-CL2A-SN-38), non-targeting control ADC (h679-CL2A-SN-38), and naked antibody hRS7-IgG for a total of 3 days.